Chantix Fact Sheet
Pfizer; patent expires 2018.
Dual mechanism of action: 1) Partial agonist at nicotinic receptors, mimicking nicotine
- effects on the brain; 2) Blocks nicotine from binding to these receptors, thereby decreasing the
- reinforcing effect of smoking.
Supplied as 0.5 mg white tablet and 1 mg light blue tablet.
- Because of high risk of nausea, titrate slowly: Days 1-3: 0.5 mg/day; Days 4-7: 0.5 mg BID;
- thereafter: 1 mg BID. Continue for 12-24 weeks depending on response.
- Most convenient way to prescribe: “Starting Month Pak,” which contains 0.5 mg x 11 tablets
- and 1 mg x 42 tablets.
- Price varies depending on pharmacy, but a month-long course costs around $130.00.
- Patients should take it after eating and with a full glass of water.
Quit rates about 40% after 3 to 4 months, vs. 30% with Zyban and 20% with placebo.
Most common: nausea (30%-40% of patients), insomnia, constipation, flatulence.
- Not a controlled substance, no abuse potential.
Can be combined with Zyban.
- When combined with nicotine replacement therapy, causes a high incidence of nausea,
- headache, vomiting, and dizziness.
- No other drug interactions
Half-life 24 hours.
- Excreted unchanged in urine, no hepatic metabolism.
Patients should set a quit date and start Chantix one week before quitting.
Earn CME Credit Instantly!
Not quite ready for a one-year subscription to The Carlat Psychiatry Report? Need CME credits on a particular topic or on a tight deadline?
Try our A la Carte CME! You can buy single or multiple credits of continuing education, without committing to a year-long newsletter subscription.
Already an A la Carte subscriber? Click here to go to your a la carte page
Steve Balt Interviewed by NPR
Our own Steve Balt was interviewed on NPR's "Talk of the Nation" on psychiatry's shift toward drugs and away from talk therapy.
After 10 years at the helm of TCPR, Dr. Carlat has handed over editor-in-chief duties to Dr. Steve Balt. We’re excited to welcome him aboard! Read More...